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Abstract
The CRISPR/Cas9 system, a natural defence system of bacterial organisms, has recently been used to modify genomes of the
most important protozoa parasites. Successful genome manipulations with the CRISPR/Cas9 system are changing the present
view of genetics in parasitology. The application of this system offers a major chance to overcome the current restriction in
culturing, maintaining and analysing protozoan parasites, and allows dynamic analysis of parasite genes functions, leading to a
better understanding of pathogenesis. CRISPR/Cas9 system will have a significant influence on the process of developing novel
drugs and treatment strategies against protozoa parasites.
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Introduction
What is CRISPR?
CRISPR (clustered regularly interspaced short palindromic
repeats) is a natural part of the genome, found in bacteria
and archaea (Barrangou and Marraffini 2014; Westra et al.
2012). It provides adaptive immunity against viruses and plas-
mids (Jinek et al. 2012) by using CRISPR RNAs (crRNAS)
that silence invading nucleic acids (Barrangou et al. 2007;
Goldberg and Marraffini 2015; Jiang and Marraffini 2015;
Makarova et al. 2011; Mali et al. 2013). It was first observed
in the 1980s in Escherichia coli (Ishino et al. 1987).
CRISPR means the grouping of short (about 20 bp) palin-
dromic sequences separated from each other on a regular basis
that isolates DNA sequences recognised as foreign- so-called
Bspacers^ (Deltcheva et al. 2011). During the adaptation stage,
a short fragment from plasmid or viral DNA is incorporated
into the CRISPR locus (Datsenko et al. 2012; Yosef et al.
2012). Selection of a sequence that is built into the host genome
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depends on the presence of the PAM (protospacer adjacent
motif) sequence in foreign DNA. PAM is a sequence of several
(2–6) nucleotides directly following the DNA sequence that
targets the Cas nuclease (CRISPR-associated protein), so the
PAM sequence is not incorporated into the genome (it is only a
nuclease-targeting element). Expression results in a long, pre-
cursor transcript (pre-crRNA) that contains all of the sequences
included repeated and separating sequences, which is then ma-
tured into the crRNA. CRISPR type II—most common in ge-
netic engineering—is characterised by the presence of trac-
crRNA, which is responsible for the maturation of the crRNA
(tracRNA hybridises with repeated sequences of pre-crRNA)
(Cong et al. 2013). The tracrRNA and pre-crRNA duplex are
hydrolysed by endoribonuclease III in the presence of the Cas9
protein. Those products are mature crRNAs containing a spacer
and partially repetitive sequence. In the last step (interference),
the crRNA directs the Cas9 protein to a complementary, foreign
sequence which is then subjected to degradation (Wang et al.
2016a).
The activity of the natural CRISPR/Cas9 type II system
differs from that used in the genome engineering. To change
the genome, it is necessary to provide the Cas9 enzyme and
sgRNA (single-guide RNA) scaffold in the form of a plasmid
transgene or a complete transcript (Yin et al. 2015). SgRNA is
a combination of the crRNAwith tracrRNA and is responsible
for recognising the target DNA (Fig. 1). As in the bacterial
system, the presence of a PAM directly after the target se-
quence is required to hydrolyse DNAvia cas9. In mammalian
cells, the Cas9 nuclease induces the formation of double-
strand breaks (DSB) which can be repaired by two primary
mechanisms. The first type of repair is a non-homologous end
joining (HDR) which occurs more often, but results in the
insertion or removal of additional nucleotides, and thus the
formation of indel (insertion/deletion) mutations (Lieber
2010). This type of repair depends, among other things, on
the activity of DNA ligase IV, heterodimeric Ku protein,
DNA-PKCS protein kinase and XRCC4 (Goldberg and
Marraffini 2015). The second type of repair—homologous
recombination (HDR)—is much less frequent, and in genome
engineering is used for precise corrections: insertion (using a
DNA template) or deletion of a specific fragment (Zhang et al.
2017). It is also possible to induce genome correction in a
particular locus by cutting and inserting the appropriate se-
quence. To enhance the HDR process and to create precise
mutations, the essential proteins of the NHEJ process: Ku70,
Ku80 and DNA ligase IVare inhibited by gene silencing or by
using inhibitors of these proteins (Chu et al. 2015). The Cas9-
sgRNA complex recognises the target sequence of sgRNA-
DNA complementarity and by interacting with Cas9 to PAM
(Fig. 1). Designing and matching a sgRNA sequence of ap-
proximately 20 nucleotides to a particular sequence enables
the induction of a cut in a strictly defined place in the genome.
Also, modifications may involve the structure of the Cas9
nuclease. Cas9 from Streptococcus pyogenes is currently
widely used in genome engineering and binds to the 5′
NGG3 PAM sequence, but this specificity can be modified
by orthologous exchange of a PAM-interacting domain in
Cas9. For example, orthologous replacement of the Cas9 do-
main from Streptococcus thermophilus with the correspond-
ing domain Streptococcus pyogenes exchange the recognised
PAM sequence from 5′-NGGNG to 5′-NGG. The Cas9 pro-
tein contains two nuclease domains: HNH and RuvC respon-
sible for the cleavage of both strands of DNA (Hsu et al.
2014). Induce of a mutation in one of the nucleic domains
allows for the formation of a Cas9 nuclease that cut only
one strand, while the mutations in both domains form Cas9
only with sgRNA-guiding activity and binding to the target
sequence (Makarova et al. 2011).
CRISPR-Cas9 system is one of the fastest developing areas
in bioscience (Doudna and Charpentier 2014). It was success-
fully applied to edit genomes in a wide range of model organ-
isms including Drosophila melanogaster (Gratz et al. 2013),
Saccharomyces cerevisiae (Dicarlo et al. 2013) and
Caenorhabditis elegans (Dickinson and Goldstein 2016).
The system has recently been used in a wide variety of
biomedical studies including stem cell research (Inak et al.
2017; Yumlu et al. 2017), neurobiology (Grzybek et al.
2017), cancer treatment (Cyranoski 2016), generation of ani-
mal models (Mali et al. 2013), somatic genome editing
(Schwank et al. 2013), correcting genetics disorders (Long
et al. 2016) and the spread and treatment of infectious diseases
(Doerflinger et al. 2017; Liao et al. 2015).
The first reports of successful protozoa genome editing
using this system were published in 2014 (Ghorbal et al.
2014). However, there is a significant number of studies under-
line the importance of these tools for genomic engineering
(Table 1). These methods became fundamental to the functional
assessment of genes (Barrangou and Horvath 2017), and they
have significantly advanced our knowledge about parasitosis.
In this review, we present findings which demonstrate the
recent progress in using CRISPR and CRISPR-associated
(Cas) genes. In our opinion, CRISPR/Cas9 system has shed
new light on parasitology, especially on protozoa parasites.
Application of CRISPR/Cas9 system
in protozoa parasites
Plasmodium falciparum
P. falciparum is the most significant protozoan species caus-
ing malaria. The use of genome editing methods, especially
CRISPR/Cas9, enables the study of genes involved in the
growth of parasites and the invasion process. In the case of
Plasmodium, it is crucial to know the gene products
responsible for the host erythrocyte invasion. A study by
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Ghorbal et al. (2014) emphasised the significance of the
CRISPR/Cas system for P. falciparum. Two techniques,
namely gene disruption and single-nucleotide gene editing,
were used to disrupt two non-essential loci, i.e. the integrated
GFP reporter gene and the kahrp gene, which encode a protein
exported into the host red blood cells. They were acquired by
inserting a selectable marker into their encoding sequences.
Other complex approaches included the modification of gene
sequences orc1 (origin recognition complex subunit 1), which
has a regulatory role in origin activation and kelch13—asso-
ciated with artemisinin resistance. Altered parasites were re-
covered with high efficiency. This was obtained despite the
absence of non-mediated range for the change, but only in the
case of the cross-transferred plasmids. This might suggest that
it is possible to generate neutral or deleterious mutations in the
CRISPR system. Similar to previous zinc finger nuclease
editing (Straimer et al. 2012), the inclusion of silent mutations
in the donor sequences seemingly enriched the desired alter-
ations within the bulk parasite population. As a result, the
donor plasmid, as well as the edited genomic locus from
cleavage, was protected.
Ghorbal et al. (2014) used a two-plasmid protocol to ex-
press both Cas9 nuclease and sgRNA. Considering the need
for an appropriate place for sgRNA transcription initiation, the
U6 promoter of the spliceosome component of small nuclear
RNA (snRNA) is necessary. The U6 transcription of snRNA
is driven by RNA polymerase III, which accurately transcribes
RNAs that do not encode proteins (non-coding RNAs). U6
product transcription initiates with a G and consists of the
motif G-N19/20-NGG, with the final three PAM (protospacer
adjacent motif) nucleotides essential for cleavage. The prod-
ucts of U6 transcription begin with a guanosine nucleotide
(G), and thus the choice of targeting sequences in the genome
is limited. The guide sequence (gRNA) pairs with the DNA
target, directly upstream of a requisite 5′-NGG adjacent motif.
Once the Cas9-gRNA complex binds a putative DNA target, a
Bseed^ sequence at the 3′ end of the gRNA targeting sequence
begins to anneal to the target DNA. Cas9 mediates a DSB ~
3 bp upstream of the PAM.
Ghorbal et al. (2014) reported that the application of the
P. falciparum U6 snRNA behind the control region made it
possible to promote sgRNA expression in the parasite but
without the need for the incipient guanosine nucleotide. This
is essential as it greatly extends potentially targeted loci in the
parasitic genome to random sequences containing the 5′-NGG
PAMpattern. It is a particularly beneficial trait of Plasmodium
spp. with a mean GC content of just 19.4%.
Plasmodium spp. lacks the mechanisms necessary for non-
homologous end joining (NHEJ) (Straimer et al. 2012).
Therefore, the use of the CRISPR/Cas compound, i.e. rift
followed by error-susceptible fixing to produce frame dis-
placement mutations, is not an option to malaria investigators.
Nonetheless, there are numerous possibilities, such as the abil-
ity to express two or more gRNAs within the same cell. This
might permit multiple cleavage instances that can produce
substantial deletions. These can be used to analyse genome
duplications that might be connected resistance to drugs.
Work by Gilbert et al. showed that a version of Cas9 without
endonuclease activity (catalytically dead Cas9; dCas9), deliv-
ered to a target gene, acts as a blocker to transcription. On the
other hand, gene expression can be increased by the merging
of this non-active Cas9 with a transcription-triggering domain
(Gilbert et al. 2013). Mutations in pfmdr1 gene are associated
with P. falciparum resistance to drugs, e.g. the point mutation
in codon 86 pfmdr1 is associated with decreased sensitivity to
chloroquine, while amplification of this gene is associated
with resistance to antimalarials (i.e. mefloquine and
halofantrine) (Antony et al. 2016).
Fig. 1 The mechanism of genome editing using CRISPR/Cas9
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Another study applied CRISPR/Cas9 to edit P. falciparum
genome (Wagner et al. 2014). They created a two-vector strat-
egy to apply T7 promoter-driven system. The team used pT7
RNAP-HR plasmid to express T7 RNA polymerase and to
deliver DNA donor sequence for DSB repair. The second
pCas9-sgRNA-T plasmid was created to express Cas9 and
sgRNA to target locus of interest. With the application of the
system, authors reported kharp gene deletion 33 days post-
transfection. What is more, the team managed to delete eba-
175 gene, which is responsible for encoding parasite ligand.
The editing efficiency between 50 and 100% was reported.
This confirms that CRISPR/Cas9 system may be applied to
edit Plasmodium spp. genome successfully.
Recent reports have underlined the reality of significant
resistance to first-line antimalarial combination therapies.
The main aim of the pharmacologists and parasitologists
working on malaria is to increase treatment efficacy (WHO
2015). Increasing resistance to artemisinin and piperaquine
has been reported recently (Amaratunga et al. 2016; Isozumi
et al. 2015), and this underlines the gravity of the situation. Ng
Table 1 Applications of CRISPR/Cas9 system in protozoa parasites
Organism Purpose Strategy Repair
mechanism
References
P. falciparum Gene knockout 2 vectors HDR Ghorbal et al., 2014
P. falciparum Gene knockout 2 vectors HDR Wagner et al., 2014
Gene knockout, C-terminal
P. yoelii tagging and insertion of point
mutations
1 vector HDR Zhang et al., 2014
T. gondi Gene knockout and knockin 1 vector NHEJ, HDR Shen et al., 2014; Behnke et al., 2015a;
Rugarabamu et al., 2015; Wang et al. 2016c
T. gondi Gene knockout, C-terminal tagging
and insertion of point mutations
1 vector NHEJ, HDR Sidiki et al., 2014
T. gondi Gene tandem replacement 1 vector HDR Behnke et al., 2015b
T. gondi Gene knockout 1 vector NHEJ Zheng et al., 2015
C. parvum Gene knockout and knockin 1 vector HDR Vinayak et al., 2015
T. cruzi Gene knockout 1 vector and 2
vectors
MMEJ, HDR Lander et al., 2015
T. cruzi Gene disruption (single, multi),
exogenous gene swapping
1 vector MMEJ, HDR Peng et al., 2014
T. brucei Gene knockin 1 vector MMEJ Beneke et al., 2017
L. major Replacement of a gene tandem 2 vectors HDR Sollelis et al., 2015, Zhang et al., 2017;
Beneke et al., 2017
L. mexicana Gene knockin 1 vector and 2
vectors
MMEJ, HDR Beneke et al., 2017; Zhang et al., 2017
L. donovani Gene knockout and C-terminal tag-
ging
2 vectors IHR, MMEJ,
HDR
Zhang and Matlashewski (2015); Zhang et al.,
2017
T. vaginalis Gene knockout and knockin 1 vector and 2
vectors
NHEJ, HDR Jannsen et al., 2018
Giardia intestinalis
Babesia spp.
Eimeria spp.
Isospora spp.
Cystoisospora spp.
Sarcocystis spp.
Naegleria fowleri ?
Entamoeba
histolytica
Acanthoamoeba
spp.
Pentatrichomonas
hominis
Balantidium coli
Spironucleus spp.
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and colleagues applied a similar strategy to Wagner et al.
(2014). They used whole-genome sequencing and the
CRISPR/Cas9 system to ratify the role of PfMDR1
(Plasmodium falciparum multidrug drug resistance gene 1)
mutations in resistance to ACT-451840, a compound that con-
tains piperazine and can affect Plasmodium asexual develop-
ment occurring in the blood (Ng et al. 2016). The piperazine-
rich compound ACT-451840 was found by the authors to
promote inhibition of asexual stages and transferrable game-
tocyte forms of P. falciparum. Genomic sequencing of in
vitro-derived ACT-451840-resistant parasites found SNPs
(single nucleotide polymorphism) in pfmdr1. It encodes a di-
gestive vacuole membrane-bound ATP-binding cassette trans-
porter responsible for altering P. falciparum receptiveness to
various first-line pharmaceuticals used against malaria. The
CRISPR/Cas9-associated editing of genes enhances the pro-
motion of ACT-451840 resistance by PfMDR1 point muta-
tions. Resistant parasites showed an improved response to
clinically applied anti-malaria drugs. pfmdr1mutation obtain-
ed via Cas9 caused resistance to ACT-451840 in fifth stage
gametocytes. This proves that PfMDR1 mutations can lead
the resistance to asexual sanguineous stages and mature ga-
metocytes by developing a response to active compounds.
The investigation of PfMDR1 resistance mechanisms opens
up new vistas in the development of new antimalarial
pharmaceutic agents (Ng et al. 2016).
A most recent study by Crawford et al. (2017) used
CRISPR/Cas-9 to introduce a drug resistance mutation in
Plasmodium. This novel attempt does not require the use of
plasmids or cloned homologous recombination templates. The
team edited PfATP4, a sodium efflux channel by CRISPR
modified RNA-protein complex and single-stranded
oligodeoxynucleotide repair mechanism. Whole-genome se-
quencing (WGS) and inhibition assay methods confirmed that
obtained mutation caused the development of resistance to an
SJ733 compound (Fig. 2) (Jimenez-Diaz et al. 2014).
What is more, authors showed that single-stranded
oligodeoxynucleotide might play a role of repair template in
P. falciparum. Obtained results demonstrate that CRISPR/
Cas-9 system can be successfully applied to edit
Plasmodium genes to study malaria drug resistance and there-
fore search for new antimalaria treatment in the future.
Toxoplasma gondii
T. gondii is an obligate, intracellular parasite in humans and
animals (Tenter et al. 2000). This species is also used as a
model for other apicomplexan parasites including
Plasmodium spp. (Wang et al. 2016b). Despite the recent
favourable developments in molecular techniques, manipulat-
ing the T. gondii genome is still not efficient (Szabo and
Finney 2017). Moreover, manipulations are restricted to
strains or lines carrying mutations that allow selection. What
is more, one of the T. gondii features is a highly clonal popu-
lation structure, and these populations differ in acute virulence
in laboratory mice. Establishing a link between the extent of
virulence factors and pathogenesis is a serious issue.
In their study, Shen et al. (2014) used the CRISPR/Cas9
system to disrupt T. gondii genes efficiently. With a combina-
tion of site-specific sgRNAs and Cas9, they disrupted the
uracil phosphoribosyltransferase (UPRT) gene which builds
resistance to fluoro deoxyribose (FUDR). This permitted
straightforward efficiency quantification and provided a
facilitative site for analyses of gene disruption frequencies.
Moreover, Shen et al. (2014) applied the CRISPR/Cas9 sys-
tem to edit the ROP18 (gondii rhoptry protein) locus from the
type 1 strain GT1 to complement this loss at the UPRT locus.
This revealed that ROP18 is a significant factor that influences
the acute virulence and confirmed previous hypotheses
(Fentress et al. 2010).
Ku80 and Ligase IV DNA are key molecules in the NHEJ
repair pathway, so their inhibition improves the efficiency of
the competitive HDR pathway. The recent generation of
NHEJ deficient strains via the elimination of KU80 has made
genome editing available. This is possible due to the suppres-
sion of the high incidence of accidental integration, naturally
occurring in T. gondii. However, this method makes use of
complex DNA constructs for homologous recombination.
This gives rise to many problems such as the necessity of
screening many clones for correct rearrangements.
Moreover, genomic engineering predominantly concerns cho-
sen, laboratory-adapted strains of the ΔKU80 T. gondii lines
mentioned previously. A recent study by Sidik et al. (2014)
reported an efficiently edited T. gondii genome via the
CRISPR/Cas9 system and solved the above issues. The team
used the RNA-guided Cas9 nuclease for the generation of
non-selection knockouts. The author introduced point muta-
tions and epitope tags into the parasite genome. Sidik and
colleagues confirmed thatΔKU80 T. gondii is more suscepti-
ble to genetic edition than wild-type. This is caused by a lack
of NHEJ machinery for double-strand breaks repair. The au-
thors have previously reported highly efficient genome editing
allowing the introduction of point mutations and epitope tags
into the T. gondii genome (Fig. 3). Another study by Sidik
et al. (2016) applied the CRISPR/Cas9 system to conduct
the first genome-wide genetic screening to analyse the con-
tribution of every single gene of T. gondii during infection
of human fibroblasts. The study identified significant num-
bers of novel genes, responsible for infection process,
unique to the phylum. Secondary screening identified the
claudin-like apicomplexan microneme protein (CLAMP) as
an invasion factor. This will help to understand parasite
metabolic needs, host specificity or resistance to drugs.
Moreover, proposed protocols enable to perform the screen-
ing within a short (around 3 weeks) period of time (Sidik
et al. 2018).
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Sequenced apicomplexan genomes contain CLAMP
throughout the genome. It performs a crucial role in asexual
P. falciparum stages. These findings offer comprehensive
functional data on T. gondii genes which will help to promote
further attempts at broadening the general perspective on in-
terventions aimed at parasite containment.
Post-transcriptional control of gene expression in protozoa
parasites is still not fully understood. Nucleo-cytoplasmic
RNA export is a crucial step in gene expression control.
UAP56 protein, the most studied splicing factor, has various
functions in the pre-spliceosome assembly and mRNA
nuclear export. Serpeloni et al. (2016) studied TgUAP56, a
component of mRNA export machinery using T. gondii as a
model organism and CRISPR/Cas9 as an editing tool. The
CRISPR/Cas9 system may be applied to monitor mRNA ex-
port factors according to the functional genomic approach by
disrupting expression of selected genes by ddCas9 (fusion of
ddFKBP with Cas9). Researchers applied the qualified Cas9/
CRISPR system to perform a genetic screening to check
whether a given parameter participated in mRNA exportation
in T. gondii. The results showed the TgRRM_1330 protein led
to the aggregation of mRNA in the nucleus as observed in the
case of TgUAP56. This study is a perfect example of
CRISPR/Cas9 system application for studying molecular pro-
cesses in parasitic protozoa. The obtained knowledge lets us
explore another mRNA export path in apicomplexans.
Cryptosporidium parvum
Recent reports have underlined the role of Cryptosporidium
spp. as a significant diarrhoeal pathogen in children (Checkley
et al. 2015; Kotloff et al. 2013; Mondal et al. 2012; Striepen
2013) As an apicomplexan, this species has a deficient num-
ber of genes (~ 3950 genes) in its genome. A multiple intesti-
nal life cycle stage, weak tractability of the parasite because of
inefficient culture methods and lack of animal models that
insufficiently imitate the development cycle have all contrib-
uted to the fact that no vaccine against cryptosporidiosis is
currently available. Furthermore, there is only one approved
drug available—nitazoxanide—but it is not a cure for all of
the adverse effects of this pathogen.
This situation may change significantly due to a recent
achievement published by Vinayak et al. (Vinayak et al.
2015). An optimisation of known genetic modification
methods led to successful transient transfection of
Cryptosporidium sporozoites. The authors have established
and optimised the transfection of C. parvum sporozoites in
tissue culture in HCT-8 cells. Transfection was done by
excystation of sporozoites from oocysts obtained from ex-
perimentally infected cows. Applied protocol allowed to
mimic the parasite intestinal phase (Gut and Nelson
1999). The use of CRISPR/Cas9 technology has allowed
detection of genes suspected of responding to neomycin
resistance. To build a C. parvum CRISPR/Cas9 system,
they constructed a plasmid where Cas9 gene was flanked
by parasite regulatory sequences, and the luciferase gene
was deactivated. Luciferase activity was restored when
C. parvum sporozoites were cotransfected with a specific
guide. Also, translational fusions between the Nluc reporter
and the neomycin resistance marker (Neo) were constructed
to focus observation on the small subset of transfected
parasites.
The authors introduced a plasmid-encoding target gene
whose short expression occurs in the cell. The verification of
successful transfection was performed using a gene that en-
codes luciferase. It lights up when the appropriate substrate is
present. This marker is linked to a gene which confers resis-
tance to neomycin-class antibiotics, this, in turn, provides a
means of selecting transferred cells.
Fig. 2 Strategy for introducing plasmid-free CRISPR/Cas9 edits to the P. falciparum gene pfatp4 without the use of plasmids. Adopted from Crawford
et al. 2017
Fig. 3 Targeted disruption of the SAG1 locus using CRISPR/Cas9.
Adopted from Sidik et al. 2014
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Cryptosporidium does not produce oocysts when cultured
in vitro. However, this issue was solved by placing engineered
sporozoites back into intestines of immunodeficient mice,
from which oocysts were collected (Fig. 4).
A significant problem with Cryptosporidium culturing
in vitro was overcome using the CRISPR/Cas9 system. The
cross-transfer of sporozoites with both the luciferase-
neomycin resistance fusional gene and DNA-coding
CRISPR/Cas9 mechanism, preceding the sporozoite infec-
tions and paromomycin treatment of the mice, allows for the
retrieval of antibiotic-resistant parasites from mouse faeces.
The parasites obtained reliably expressed an integrated lucif-
erase gene. The application of CRISPR/Cas9 system permit
genetic modification and culturing (Pawlowic et al. 2017) of
this significant parasite and will hopefully bring rapid ad-
vances in overcoming cryptosporidiosis.
Trypanosoma spp.
Trypanosoma cruzi is a protozoan parasite that infects both
humans and animals. It affects more than 10 million people
(Jones et al. 2008). It is the causative agent of Chagas’ disease.
T. cruzi is the least well-understood protozoan in a group of
neglected tropical diseases, being responsible for infection-
induced heart disease. The complexity of T. cruzi genetics
and the lack of efficient biomolecular tools for genome editing
have created a significant barrier to the investigation of this
organism.
However, this situation might be changing given the recent
findings of Peng et al. (2014), who adapted the CRISPR-Cas9
system for quick and efficacious suppression of numerous
endogenous genes, including crucial T. cruzi genes.
Researchers have designed sgRNAs targeting the α-tubulin
and histidine ammonia lyase (HAL) genes, respectively, while
the ability of sgRNA to effectively disruption of gene expres-
sion was determined by the loss of GFP expression in the
parasites studied. The disappearance of a template effectuating
the fixing of the Cas9-incited DSBs in T. cruzi is brought
about only through microhomology-mediated end joining
(MMEJ) (Glover et al. 2008, 2011) with deletions of different
sizes. This DNA repair template provided homologous recom-
bination which led to DSB repair with efficiency several times
higher than it is without CRISPR-Cas9-induced DSBs. What
is more, Peng et al. demonstrated the significant multiplexing
capability of CRISPR-Cas9 in T. cruzi by suppressing the
expression of a sizeable family of enzyme genes (β-
galactofuranosyl glycosyltransferase family). This led to a
substantial diminishment of the enzymatic product with no
visible mutations off the target.
Lander et al. (2015) performed three different types of
T. cruzi gene disruption using the CRISPR/Cas9 system.
The team silenced GP72 protein genes—connected with in-
fectivity—which is necessary for correct flagellar attachment
by using vectors containing sgRNA and Cas9. Moreover, sig-
nificant components of the parasite flagellum such as PFR1,
PFR2 were silence as well. Lander et al. used a vector that
contained sgRNA and Cas9 as well as donor DNA for homol-
ogous recombination to create cell lines with the following
modified genes: PFR1, PFR2 and GP72 (Lander et al. 2015)
(Fig. 5). This confirmed that the CRISPR/Cas9 system might
be applied to modify the T. cruzi genome without the adverse
effects of Cas9 toxicity. What is more, the PFR1, PFR2 and
GP72 genes are responsible for the motility of the parasite.
Another study, by the same group, reports application of
CRISPR/Cas9 system in tagging genes of T. cruzi. Results con-
firm that genes of known (flagellar calcium bining (TcFCaB),
vacuolar proton pyrophosphatase (TcVP1) and unknown loca-
tions (mitochondrial calcium uniporter (TcMCU) and inositol
1,4,5-trisphosphate receptor (TcIP3R)) may be tagged using
CRISPR/Cas system. This may be applied to characterise loca-
tions and functions of T. cruzi proteins (Lander et al. 2016b).
Moreover, formation of a protocol to generate CRISPR/Cas9-
mediated endogenous gene tagging will enable analysis of pro-
tein–protein interactions in Trypanosoma spp. (Lander et al.
2017). This novel approach may be applied in both T. cruzi
and T. brucei to study targets for drugs or vaccines against
kinetoplastid parasites (Chiurillo et al. 2017). CRISPR applica-
tion caused an improvement in these parasite genome function-
al analyses (Lander et al. 2016a). These results have established
a robust novel tool for the analysis of the gene functions of
Trypnosoma spp., a barely genetically tractable parasite.
Leishmania spp.
Leishmania spp., a protozoan parasite, causes fatal human
visceral (VL), cutaneous (CL) and mucocutaneous (MCS)
leishmaniasis. These obligate parasites of host macrophages
are transferred by over 30 various species of phlebotomine
sandflies (Pavli and Maltezou 2010). Leishmaniasis consti-
tutes the secondmost problematic infectious disease the world
over, present in more than 98 countries, threatening over 350
million people (Ejov and Dagne 2014).
Genetic manipulations are problematic in leishmaniasis
species since multiple cloning and transfection steps are
necessary to generate null mutants for targeted genes.
However, a recent application of the CRISPR/Cas9 system
enables highly efficient Leishmania genome editing. Sollelis
et al. (2015) expressed Cas9 endonuclease controlled with the
following promoter: dihydrofolate reductase–thymidylate
synthase (DHFR-TS). Subsequently, the single-guide RNA
was generated under the control of the promoter and termina-
tor U6snRNA. The team targeted the paraflagellar rod-2 locus,
a tandemly repeated gene family. What is more, the authors
obtained null mutants in a single round of transfection. Entire
genome sequencing of two independent clones confirmed the
absence of off-target editions.
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Another study applied CRISPR/Cas9 system into
L. donovani and successfully produced guide RNA expression
vectors through the L. donovani rRNA promotor and
ribozyme of the hepatit is delta virus. Zhang and
Matlashewski (2015) were able to produce knockout with no
selection through the insertion of an oligonucleotide donor
containing stop codons as well as 25-nucleotide homology
arms in the Cas9 cleavage site. They disjointed and accurately
marked endogenous genes through the insertion of a
bleomycin drug choice marker and reporter gene (GFP) in
the Cas9 cleavage site. Hammerhead and HDV ribozymes
are self-processed from the gRNA they were employed to
create a double-gRNA expression vector to express two
gRNAs at the same time. This application caused the deletion
of the 3-kb miltefosine transporter gene (LdMT) what cause
improvement in gene inactivation efficiency. The authors re-
port a novel single point mutation in LdMT (M381T) that was
linked to miltefosine resistance. This was a concern for the
only available oral treatment against leishmaniasis. Most im-
portantly, the authors report that L. donovani chiefly used
HDR and MMEJ to fix the Cas9 nuclease-generated DSB.
The NHEJ path seems to be absent in L. donovani. These
observations corroborate the view that the CRISPR-Cas9
system constitutes an efficient genome engineering instru-
ment for L. donovani. The successful application of the
CRISPR/Cas9 system (i.e. production of gene knockouts)
confirms that it is a useful and multifunction tool for leish-
maniasis research.
Fig. 5 Generation of a TcPFR2-
KO mutant by CRISPR/Cas9-
induced homologous recombina-
tion. A DS gDNA break was ob-
tained by Cas9 at nt +40 of the
TcPFR2 open reading frame.
DNAwas repaired with a linear
blasticidin S deaminase cassette
containing 100-bp homologous
regions from the TcPFR2 locus.
Adopted from Lander et al. 2015
Fig. 4 Modification and culture
ofCryptosporidium.Adopted and
reproduced from Vinayak et al.,
2015
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Amost recent study byBeneke et al. applied CRISPR/Cas9
system technology in Leishmania and presented a toolkit that
allows the tagging and disruption of parasite genes. The au-
thors bypassed cloning step in bacteria by generating sgRNA
and repair DNA by PCR (Fig. 6).
Presented protocols are a significant step in editing
kinetoplastids genomes and provide excellent tools to perform
large-scale knockout screens (Beneke et al. 2017). Moreover,
development of easy to perform and rapid methods for assess-
ment of gene functions (Soares Medeiros et al. 2017) will
contribute to decrease of costs and time in developing new
successful therapies against kinetoplastid parasites.
Trichomonas vaginalis
Trichomonas vaginalis is a pear-shaped, motile parasitic pro-
tozoan (Johnston and Mabey 2008). Trichomoniasis is one of
the most prevalent sexually transmitted disease (Poole and
McClelland 2013), with more than 174 million new cases
worldwide (Huppert 2009). The parasite causes the vaginal
pH increase and epithelial breaks and inflammation via
toxication (Petrin et al. 1998).
A complex application of CRISPR/Cas9 system in
T. vaginalis was reported recently by Janssen and colleagues
(2018). In vivo expression of Cas9 is known to cause prob-
lems related to its toxicity (Peng et al. 2014). However, exper-
iments with T. vaginalis shown that Cas9 toxicity may be
decreased by regulation of FKBP-DD and Shield-1 expres-
sion. Low concentration of Shield-1 caused a significant in-
crease in stabilisation of FKBP-Cas9 protein. A significant
issue in homologous gene replacement in T. vaginalis is
caused by low transfection efficiency. The team used
nucleofection (Burkard et al. 2007) to increase transfection
efficiency. The application of nucleofection causes a 20-fold
enhancement of transfection efficiency. It makes able to intro-
duce multiple DNA elements into a single cell of the parasite.
Authors proposed a protocol for CRISPR/Cas9-directed ho-
mologous recombination that enables to knockout genes, what
is a novum in T. vaginalis genome editing (Brás et al. 2013;
Land et al. 2004). Using CRISPR-Cas9-mediated homology
repair, they knockout ferredoxin-1 and mif genes. Presented
molecular methods for modification of T. vaginalis genome
allow to study gene function and therefore pathogenesis of this
parasite.
What is next?
CRISPR-Cas systems are tour de force achievement in molec-
ular parasitology. CRISPR-Cas system genomemanipulations
are efficient and should contribute to the discovery of new
treatment possibilities. CRISPR-Cas system may be applied
to generate immunogenic and non-pathogenic parasites that in
the future can serve as immunisation or vaccination
(Hollingdale and Sedegah 2017). What is more, validation
of clinical and population studies obtained by genome-wide
association studies will help with the development of new
antiparasitic drug targets (Visscher et al. 2017). CRISPR-Cas
system may be used to create libraries applied in drug mech-
anism research. The CRISP/Cas system might be used for the
investigation of genes participating in infection processes.
These methods will ameliorate the functional analysis of par-
asite genes which enables the effective engineering of their
genomes. What is more, the development of an inducible sys-
tem allowing the targeting of essential genes is highly signif-
icant and urgent (Kostro et al. 2015). It is now entirely credible
to assert that protozoa parasites have joined the CRISPR/
Cas9-based technologies and there is hope that this system
will be applied in other parasitic species (Table 1), such as
Fig. 6 Co-transfection of two
PCR amplicons allowed precise
insertion of marker genes. PCR-
amplified donor DNA containing
30 nt HF specific to the target lo-
cus, a fluorescent protein tag and
a drug-selectable marker gene.
Adapted from Beneke et al. 2017
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Giardia intestinalis, Eimeria spp. or Babesia spp. in the
nearest future.
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